ArticleBMC infectious diseases2021
Pseudomonas aeruginosa device associated - healthcare associated infections and its multidrug resistance at intensive care unit of University Hospital: polish, 8.5-year, prospective, single-centre study.
Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 77 citations in OpenAlex.
- RsmW is an iron-responsive 3' UTR derived small regulatory RNA that contributes to biofilm formation and virulence ofbioRxiv : the preprint server for biology · 2026Article
- Clinical Impact of Multidrug-Resistant Bacterial Infections in Critically Ill Patients: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Isolation and characterization of bacteriophages against antibiotic-resistanceIranian journal of microbiology · 2026Article
- ASO-functionalized gold nanoparticles for gene silencing in drug-resistant Pseudomonas aeruginosa: a proof-of-concept study.Scientific reports · 2026Article
- Preliminary study on the effects of sub-MIC concentrations of octenidine and polyhexanidine on biofilms produced by animal isolates of Pseudomonas aeruginosa.BMC microbiology · 2026Article
- Optimized green zinc oxide/chitosan/amoxicillin nanocomposite against Pseudomonas aeruginosa.Applied microbiology and biotechnology · 2026Article
- A Multifunctional Therapeutic Platform: Ce/Zn/Sr-Doped Mesoporous Bioactive Glass Nanoparticles for Bone Repair.International journal of molecular sciences · 2026Article
- An improved algorithm to screen for carbapenemase production inJAC-antimicrobial resistance · 2026Article
- Improving Microbiological Monitoring of Hospital Surfaces: Loop-Mediated Isothermal Amplification (LAMP) as a New Approach for Rapid Nosocomial Pathogens Detection.International journal of environmental research and public health · 2026Article
- Mechanisms ofMedicina (Kaunas, Lithuania) · 2026Review
- Inhibition of <italic>Pseudomonas aeruginosa</italic> Biofilm Formation by Peptidyl-Arginine Deiminases 2 and 4.Journal of innate immunity · 2026Article
- Comprehensive chemical profiling and bioactivity assessment of Porodaedalea pini and Phellinus tremulae.Scientific reports · 2025Article
- Features of Carbapenem-resistant Gram-negative Bacterial Infections in Japan Based on the Setting of Onset.Open forum infectious diseases · 2025Article
- Molecular and genomic insights into multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa causing burn wound infections in Bangladesh.Scientific reports · 2025Article
- Myricetin Potentiates Antibiotics Against ResistantBiology · 2025Article
- Accurate Diagnosis ofAntibiotics (Basel, Switzerland) · 2025Article
- Quorum Quenching ofPathogens (Basel, Switzerland) · 2025Article
- Infected burn wound healing using Hydroxy-propyl-methyl cellulose gel containing bacteriophages againstIranian journal of microbiology · 2025Article
- Evaluation of Biofilm Formation, Alginate Production, Pattern of Drug Resistance, and the Presence of Efflux PumpTanaffos · 2025Article
- Colistin Use for the Treatment of Multi-Drug-Resistant Gram-Negative Severe Infections in ICU Patients: A Single-Center Study.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPseudomonas aeruginosa has recently shown to be one of the most important strains of bacteria and alert pathogens in Europe among Intensive Care Unit patients that provide serious therapeutic problems because of its multidrug resistance.
methodsThe purpose of this microbiological study was data analysis of device associated- healthcare associated infections (DA-HAIs) in an ICU in terms of the incidents of P.aeruginosa strain infections and its susceptibility within an 8.5-year observation.
resultsAmong 919 isolated strains responsible for 799 DA-HAIs (17,62 ± 1,98/1000 patient-days) in 4010 ICU patients P.aeruginosa was the pathogen in 108/799 (13.52%) cases. Incidence rate (density) of: VAP/1000 MV- days, UTI /1000 UC- days and CLA-BSI/1000 CL- days were 11,15 ± 2.5, 6.82 ± 0.81, 2.35 ± 1.54.respectivelly. P.aeruginosa was the pathogen most frequently responsible for VAP 69/108 (63.88%). Mean frequency of VAP, UTI and CLA-BSI with P.aeruginosa etiology was 69/493 (14.28%), 32/299 (11.1%) and 7/127 (5.77%) respectively. The mean density of P.aeruginosa infection amounted to 2.43/1000 patient-days. The decrease was observed in the total number of DA-HAIs caused by the P.aeruginosa from 15.75% and 3.23/1000 patient-days in 2011 to 5.0% and 1.17/1000 in 2016 (p = 0.0104, p = 0.0348). Starting from 2016 to 2019 incidence and density of P.aeruginosa DA-HAIs increased to 12.33% and 2.63/1000 (p = 0.1388, p = 0.0818). P.aeruginosa was susceptible to ceftazidime, cefepime, amikacin, meropenem, ciprofloxacin, colistin, in 55.55, 58.33, 70.37, 53.73, 50, and 100% respectively. MDR characterised it in 40% in 2011 and 66.7% in 2019, (p = 0.177).
conclusionsThe study revealed a changeable prevalence of P. aeruginosa strain infections; however their frequency was never highest in our ICU patients as it presented in the last years in Europe. The study showed a significant decrease in 2016 and increase in 2019, a nearly 3-fold increase of P.aeruginosa infections among Gram-negative strain infections, and a 2-fold increase of the P.aeruginosa DA-HAIs frequency between 2016 and 2019 as well as an increased resistance. Microbiological analysis of DA-HAIs in each hospital should be a standard method used in hospital infection control and antibiotic policy. In the case of P.aeruginosa, in order to minimize transmission, preventive infection methods should be assessed mainly in case of VAP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.